Board votes at a glance: regulatory and legislative positions taken in June 2025 meeting

The California State Board of Pharmacy recorded several formal votes at its June 2025 meeting. This roundup lists motions the board adopted or considered and the outcomes recorded on the meeting transcript. Where available, the mover/second and roll‑call outcomes are noted.

• Adoption of proposed amendment to Title 16 §1713 (APDS consultations) - Motion: adopt proposed regulatory text as noticed and authorize the executive officer to complete rulemaking and make technical changes. - Mover: Renee Barker. Second recorded. - Outcome: approved (roll‑call unanimous yes). See agenda item 11.

• Withdraw rulemaking for Title 16 §1711 (quality assurance programs) and delegate drafting to Maria Serpa and KK John - Motion: withdraw the in‑process rulemaking and authorize designated members to draft revised language with staff before committee review. - Outcome: approved (roll‑call unanimous yes). See agenda item 12.

• Initiate rulemaking to add proposed Title 16 §1707.51 (accessible prescription labels) - Motion: initiate rulemaking consistent with board discussion; authorize executive officer to refine the language and submit for pre‑notice review. - Board direction: remove requirement that each staff sign a copy of the policies; instead require documentation of training and allow electronic records. - Outcome: approved (roll‑call unanimous yes).

• Approve updates to board FAQs (Ask the Inspector and AB1286 medication error FAQs) - The board voted to approve updates to a set of FAQs related to the Ask the Inspector program and to FAQs implementing AB 1286 (medication error reporting, and registration with ISMP for community pharmacy reporting). - Outcome: approved (roll‑call unanimous yes for both FAQ packages as presented).

• Committee recommendations on inspections, citation data, and ADDS QA reporting - The Enforcement & Compounding Committee recommended staff develop a standardized ADDS QA template, update FAQs, and conduct outreach to improve reporting consistency. This was recorded as a committee recommendation for staff action and follow‑up rather than as a separate board motion needing a roll call.

• Legislative positions (committee recommendations carried to the board) - The board recorded votes maintaining support/watch positions on numerous measures reviewed by the Legislation & Regulation Committee. Motions were presented and approved by roll call. Selected measures and the board’s recorded position include: - AB 50 (pharmacist‑furnished OTC contraception, 12‑month supply) — support (approved) - AB 309 (pharmacists furnishing needles/syringes permanently) — support (approved) - AB 529 (waiver extension after declared emergency) — support (approved) - AB 669 (substance use disorder treatment access) — support (approved) - AB 957 (prohibit pharmacies selling tobacco products) — support (approved) - AB 968 (pharmacist furnishing of non‑hormonal contraception / 12‑month supply) — support (approved) - AB 1460 (restrictions on manufacturer discriminatory practices affecting 340B) — support (approved) - AB 1503 (board sunset bill / policy changes; includes pharmacy technician advisory committee and proposed ratio changes) — support (approved) - SB 40 (insulin affordability cap / step therapy restrictions) — support (approved) - SB 41 (PBM regulation, DOI licensing under DMHC oversight) — support (approved) - SB 306 (prior authorization exemption for services approved most of the time) — support (approved) - SB 470 (Bagley‑Keene meeting flexibilities extension) — support (approved) - SB 497 (protections for release of medical records related to gender‑affirming care) — support (approved) - SB 641 (waivers for boards during disasters; email requirement for licensees) — support (approved)

- For each legislative item the committee recommended a board position; the board then adopted the committee’s recommended position by roll call. The meeting transcript records each roll‑call yes vote by board member for these measures.

Why it matters: these votes direct board staff priorities for regulatory drafting, public guidance, inspections, and legislative engagement. They affect pharmacy operations, medication safety reporting, access to medications and services, and patient communication/accessibility statewide.

What’s next: staff will implement the board’s instructions—finalize adopted regulations, reopen and rework withdrawn rulemaking, publish FAQ updates, prepare draft rule text for accessible labels, and continue outreach on ADDS QA reporting. The legislature‑related positions will be communicated as the bills advance.